Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025

Author: Benzinga Newsdesk | October 21, 2025 07:08am
  • ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~
    • ~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in "Best of Journal of the American Medical Association and the New England Journal of Medicine" presentation~

Posted In: MLYS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist